Antipsychotic Agent with Potential as PAH Treatment Named Orphan Drug by FDA
The U.S. Food and Drug Administration (FDA) has designed Reviva Pharmaceuticals’ RP5063 an Orphan Drug as a potential treatment of pulmonary arterial hypertension (PAH), providing the company with developmental and testing assistance. “We are pleased to receive Orphan Drug Designation for RP5063, which emphasizes the significant need for new mediations for patients…